Physician profile
Gary Volkell
NPI 1679937338
$6,118.15
in general payments reported to CMS, 2019-2025
35 companies · $2,394 in 2025
The $2,394 reported for 2025 was more than what 75% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $259 · 2020: $113 · 2021: $240 · 2022: $990 · 2023: $551 · 2024: $1,570 · 2025: $2,394.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,902 · Travel and Lodging: $613.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,902.28 |
| Travel and Lodging | $613.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,138.30 | 2022-2025 | Ubrelvy, Qulipta |
| Biogen, INC. | $924.07 | 2021-2025 | Vumerity, Tysabri, Avonex |
| Ipsen Innovation | $909.33 | 2025 | |
| Neurocrine Biosciences, INC. | $500.76 | 2021-2025 | Ingrezza |
| Amneal Pharmaceuticals LLC | $300.55 | 2022-2025 | Crexont |
| Eisai INC. | $289.30 | 2024-2025 | |
| Acorda Therapeutics, INC | $274.57 | 2019-2023 | Inbrija, Ampyra |
| Supernus Pharmaceuticals, INC. | $186.43 | 2025 | Qelbree |
| Allergan, INC. | $164.18 | 2020-2021 | |
| Acadia Pharmaceuticals INC | $156.03 | 2022-2024 | Nuplazid |
| Revance Therapeutics, INC. | $143.21 | 2024-2025 | Daxxify |
| Lilly USA, LLC | $129.69 | 2022-2025 | Kisunla, Amyvid, Emgality |
| Genentech USA, INC. | $118.24 | 2022-2025 | Ocrevus Zunovo, Ocrevus |
| Medtronic, INC. | $82.56 | 2024 | Percept Pc Brainsense |
| Mdd US Operations, LLC | $66.43 | 2024 | Gocovri |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $63.78 | 2022 | |
| Ucb, INC. | $62.35 | 2022-2024 | Briviact, Nayzilam |
| Teva Pharmaceuticals USA, INC. | $58.09 | 2021-2022 | |
| Tanabe Pharma America, INC. | $51.00 | 2025 | Radicava |
| Banner Life Sciences, LLC | $50.19 | 2023 | |
| Horizon Therapeutics Plc | $49.70 | 2022-2023 | Uplizna |
| Janssen Pharmaceuticals, INC | $48.14 | 2022-2023 | Ponvory |
| Livanova USA, INC. | $42.85 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $35.13 | 2024 | Dysport |
| Avion Pharmaceuticals | $35.04 | 2022 | |
| Argenx US, INC. | $33.53 | 2022 | |
| Merz Pharmaceuticals, LLC | $29.36 | 2024 | Xeomin |
| Alexion Pharmaceuticals, INC. | $26.44 | 2022 | |
| Genzyme Corporation | $24.45 | 2025 | |
| Tg Therapeutics, INC. | $24.38 | 2025 | |
| Lundbeck LLC | $23.48 | 2022 | |
| Amgen INC. | $22.90 | 2023 | Aimovig |
| Pfizer INC. | $21.18 | 2025 | |
| Novartis Pharmaceuticals Corporation | $17.21 | 2022 | |
| Celgene Corporation | $15.30 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Volkell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.